These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 35488862)
1. Determination of plasma protein binding of dalbavancin. Turner NA; Xu A; Zaharoff S; Holland TL; Lodise TP J Antimicrob Chemother; 2022 Jun; 77(7):1899-1902. PubMed ID: 35488862 [TBL] [Abstract][Full Text] [Related]
2. Dalbavancin: a lipoglycopeptide antibacterial for Gram-positive infections. Roecker AM; Pope SD Expert Opin Pharmacother; 2008 Jul; 9(10):1745-54. PubMed ID: 18570607 [TBL] [Abstract][Full Text] [Related]
3. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Andes D; Craig WA Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987 [TBL] [Abstract][Full Text] [Related]
4. Plota M; Papadimitriou-Olivgeris M; Kolonitsiou F; Tsiata E; Spiliopoulou I; Assimakopoulos SF; Marangos M J Med Microbiol; 2021 Sep; 70(9):. PubMed ID: 34559042 [No Abstract] [Full Text] [Related]
5. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial. Turner NA; Zaharoff S; King H; Evans S; Hamasaki T; Lodise T; Ghazaryan V; Beresnev T; Riccobene T; Patel R; Doernberg SB; Rappo U; Fowler VG; Holland TL; Trials; 2022 May; 23(1):407. PubMed ID: 35578360 [TBL] [Abstract][Full Text] [Related]
6. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin. Steele JM; Seabury RW; Hale CM; Mogle BT J Clin Pharm Ther; 2018 Feb; 43(1):101-103. PubMed ID: 28628223 [TBL] [Abstract][Full Text] [Related]
7. Dalbavancin: a review. Scheinfeld N Drugs Today (Barc); 2007 May; 43(5):305-16. PubMed ID: 17724497 [TBL] [Abstract][Full Text] [Related]
8. Dalbavancin for the treatment of acute bacterial skin and skin structure infections. Ramdeen S; Boucher HW Expert Opin Pharmacother; 2015; 16(13):2073-81. PubMed ID: 26239321 [TBL] [Abstract][Full Text] [Related]
9. Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model. Baldoni D; Furustrand Tafin U; Aeppli S; Angevaare E; Oliva A; Haschke M; Zimmerli W; Trampuz A Int J Antimicrob Agents; 2013 Sep; 42(3):220-5. PubMed ID: 23880168 [TBL] [Abstract][Full Text] [Related]
10. Dalbavancin for the treatment of acute bacterial skin and skin structure infections. Esposito S; Noviello S; Leone S Infez Med; 2015 Dec; 23(4):313-7. PubMed ID: 26700080 [TBL] [Abstract][Full Text] [Related]
11. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015). Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053 [TBL] [Abstract][Full Text] [Related]
12. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016). Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526 [TBL] [Abstract][Full Text] [Related]
13. Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: A case report. Hakim A; Braun H; Thornton D; Strymish J Int J Infect Dis; 2020 Feb; 91():202-205. PubMed ID: 31841726 [TBL] [Abstract][Full Text] [Related]
14. Dalbavancin in the treatment of different gram-positive infections: a real-life experience. Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A; Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276 [TBL] [Abstract][Full Text] [Related]
15. Anti-biofilm activity of dalbavancin against methicillin-resistant Silva V; Miranda C; Bezerra M; Antão HS; Guimarães J; Prada J; Pires I; Maltez L; Pereira JE; Capelo JL; Igrejas G; Poeta P J Chemother; 2021 Nov; 33(7):469-475. PubMed ID: 33904369 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of intraosteoblastic activity of dalbavancin against Staphylococcus aureus in an ex vivo model of bone cell infection. Chauvelot P; Dupieux-Chabert C; Abad L; Souche A; Ferry T; Josse J; Laurent F; Valour F; J Antimicrob Chemother; 2021 Oct; 76(11):2863-2866. PubMed ID: 34423360 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. Nicolau DP; Sun HK; Seltzer E; Buckwalter M; Dowell JA J Antimicrob Chemother; 2007 Sep; 60(3):681-4. PubMed ID: 17631507 [TBL] [Abstract][Full Text] [Related]
18. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen. Werth BJ; Jain R; Hahn A; Cummings L; Weaver T; Waalkes A; Sengupta D; Salipante SJ; Rakita RM; Butler-Wu SM Clin Microbiol Infect; 2018 Apr; 24(4):429.e1-429.e5. PubMed ID: 28782651 [TBL] [Abstract][Full Text] [Related]
19. French national cohort of first use of dalbavancin: A high proportion of off-label use. Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E; Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471 [TBL] [Abstract][Full Text] [Related]
20. Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept. Cojutti PG; Rinaldi M; Gatti M; Tedeschi S; Viale P; Pea F Int J Antimicrob Agents; 2021 Nov; 58(5):106445. PubMed ID: 34614441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]